# Finland Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Finland HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Finland (FIN)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $2.0B
- Products: 43
- Buyer markets: 29
- Average CAGR: +11.1%
- Global sector size: $776.6B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $298.1B | $1.6B | $110.9B | +9.9% | 19 | +0.4% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $166.5B | $2.2M | $66.5B | -8.4% | 16 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $33.0B | $15.4M | $35.7B | +39.7% | 6 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $19.3B | $542.2 | $34.4B | -10.1% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $24.9B | $282.7K | $20.9B | +5.3% | 5 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.1B | $4.4M | $15.0B | +21.3% | 6 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $26.4B | $8.8M | $15.0B | -9.8% | 5 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $24.4B | $6.5M | $14.7B | +4.9% | 7 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $8.0B | $767.4K | $12.3B | +19.1% | 5 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $13.4B | $31.8M | $12.2B | +41.7% | 5 | +0.3% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $10.9M | $11.7B | +9.9% | 2 | +0.1% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $6.8B | $787.3 | $9.6B | -14.2% | 2 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $6.1B | $943.0 | $8.3B | -17.9% | 2 | +0.1% |
| HS 282200 - Cobalt oxides and hydroxides: commercial cobalt oxides | $4.1B | $357.3K | $7.7B | -10.3% | 2 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $98.1M | $7.2B | +11.8% | 2 | +0.8% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $23.1K | $6.6B | +1.6% | 1 | +1.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $7.8B | $60.2 | $6.3B | -36.1% | 2 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $144.7M | $6.1B | +14.3% | 3 | +0.9% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $5.2M | $5.9B | +30.9% | 2 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $5.0B | $1.4M | $5.6B | +58.4% | 3 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $4.7M | $4.1B | +15.7% | 2 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $1.7M | $3.8B | +18.8% | 2 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $8.4M | $3.3B | +13.4% | 2 | +0.2% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $3.2B | $0.4 | $3.1B | -44.2% | 1 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $3.1B | $659.5K | $2.9B | +13.9% | 2 | +0.0% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $409.8K | $2.4B | +339.0% | 1 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $22.4M | $2.3B | +6.6% | 1 | +1.8% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $32.6M | $2.3B | +65.4% | 1 | +2.2% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $558.6K | $2.2B | +36.9% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $44.5K | $2.0B | +2.9% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $98.6K | $2.0B | -1.1% | 1 | +0.0% |
| HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $463.1 | $1.9B | -3.7% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $320.6 | $1.8B | -2.2% | 1 | +0.0% |
| HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $3.0M | $1.8B | +25.6% | 1 | +0.2% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $333.5K | $1.8B | +26.2% | 1 | +0.0% |
| HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $5.0 | $1.7B | -37.2% | 1 | +0.0% |
| HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $1.2K | $1.5B | -21.3% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $16.5 | $1.4B | -24.6% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $5.9K | $1.4B | +7.4% | 1 | +0.0% |
| HS 382370 - Industrial fatty alcohols | $1.0B | $1.0 | $1.3B | -25.1% | 1 | +0.0% |
| HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $1.6M | $1.3B | +5.4% | 1 | +0.2% |
| HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $15.9 | $1.3B | +27.4% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $144.5K | $1.2B | +10.8% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $152.8B calculated opportunity across 21 products.
- China (CHN): $42.5B calculated opportunity across 15 products.
- Germany (DEU): $38.3B calculated opportunity across 12 products.
- Switzerland, Liechtenstein (CHE): $37.8B calculated opportunity across 5 products.
- Belgium (BEL): $29.3B calculated opportunity across 5 products.
- Netherlands (NLD): $19.6B calculated opportunity across 5 products.
- Italy (ITA): $13.3B calculated opportunity across 4 products.
- Canada (CAN): $13.1B calculated opportunity across 7 products.
- United Kingdom (GBR): $11.1B calculated opportunity across 5 products.
- Slovenia (SVN): $9.7B calculated opportunity across 1 products.
- Japan (JPN): $9.5B calculated opportunity across 3 products.
- Mexico (MEX): $9.4B calculated opportunity across 4 products.

## Growth stars

- HS 290121: +339.0% average CAGR, $2.4B calculated opportunity.
- HS 282590: +65.4% average CAGR, $2.3B calculated opportunity.
- HS 290919: +58.4% average CAGR, $5.6B calculated opportunity.
- HS 382600: +41.7% average CAGR, $12.2B calculated opportunity.
- HS 300214: +39.7% average CAGR, $35.7B calculated opportunity.
- HS 290531: +36.9% average CAGR, $2.2B calculated opportunity.
- HS 330499: +30.9% average CAGR, $5.9B calculated opportunity.
- HS 290110: +27.4% average CAGR, $1.3B calculated opportunity.
- HS 370790: +26.2% average CAGR, $1.8B calculated opportunity.
- HS 310540: +25.6% average CAGR, $1.8B calculated opportunity.

## Diversification opportunities

- HS 300490: 19 buyer markets, $110.9B calculated opportunity.
- HS 300215: 16 buyer markets, $66.5B calculated opportunity.
- HS 300439: 7 buyer markets, $14.7B calculated opportunity.
- HS 300214: 6 buyer markets, $35.7B calculated opportunity.
- HS 382499: 6 buyer markets, $15.0B calculated opportunity.
- HS 300220: 5 buyer markets, $20.9B calculated opportunity.
- HS 300212: 5 buyer markets, $15.0B calculated opportunity.
- HS 284190: 5 buyer markets, $12.3B calculated opportunity.
- HS 382600: 5 buyer markets, $12.2B calculated opportunity.
- HS 293719: 3 buyer markets, $34.4B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.